Liam Neeson stars as Matthew Scudder in "A Walk Among the Tombstones." ; Credit: Universal Pictures

Screenwriter and director Scott Frank has been trying to make “A Walk Among the Tombstones” for more than a decade, but it wasn't until Liam Neeson signed on that his efforts finally came into view.

Based on the Lawrence Block novel, “Tombstones” stars Liam Neeson as Matthew Scudder, an ex-cop working as an unlicensed private investigator. He agrees to help a well-to-do drug trafficker hunt down the kidnappers who have brutally murdered his wife.

Frank wrote the screenplay and, after the departures of other attached directors, Frank decided to step behind the cameras himself. 

When he came by The Frame studio, Frank spoke with host John Horn about Neeson's great strengths as an action hero and how he convinced Neeson to sign on to the project.

Interview Highlights:

John Horn: Liam Neeson has evolved in a fascinating way as an action hero. When did you start having conversations with him about this movie, and what was it about him as an actor that made it feel like the right fit?

"Well, what's interesting is that Larry Block, the novelist, had always said, going way back to 2003 or something, that the perfect actor for this, after [he saw] 'Michael Collins'...would be Liam Neeson. Chris Andrews, who is Liam's agent, always loved the script and was always trying to find a way to put it together, and he's the one who gave it to Liam back when D.J. [Caruso] was going to direct. So the first time I met Liam to talk about the movie, I was talking to him as the writer, not as the director of the movie. And then when D.J. fell out to go do a different movie at Sony...we had a conversation about directing the movie.

JH: Was this before or after the first "Taken" had come out?

This was well after the first 'Taken,' this was right before the second 'Taken.'

JH: So Liam is...succeeding as a version of that character, and I wonder if that success cuts both ways, that maybe there's a reluctance on his part to not do something that's quite as similar? Or is that part of your conversation that you have with him? 

It absolutely cuts both ways, and that was a huge part of the conversation because there's a kidnapping in this story, and there he is on the telephone for a few minutes at the end of the movie talking to kidnappers, and there are similarities [to 'Taken']. And he knew that was the way to sell the movie, and so he was very reluctant. And I talked to him and I had him watch 'Klute,' and I said, "That's the movie we're gonna make. We're not going to make 'Taken,' we're going to make a movie that's like 'Klute,' or a little bit like 'Dirty Harry,' or one of those old-school '70s films. It's going to feel more like that than an action movie."

JH: Liam Neeson's not physically imposing, but there's something about him that really kind of makes the hair on the back of your neck stand up. What is it about him as an actor in this kind of part?

Well, there's a couple things. One: you believe him. No matter what he's talking about, it seems authentic and true...he has this thing about him that, whatever he's doing, you believe him. Two: he's one of those actors like Gene Hackman where he can convey exposition and make it feel like character. He can talk pages of exposition and make it all feel like it's character and drama — it's a great thing. The other thing about him is that he has this real gravitas, and it almost borders on sadness sometimes; it's interesting when you watch him and you feel like there's all this other life going on behind him.

JH: That he has nothing to lose, in other words.

Nothing to lose, and he says that at one point in the film, but I think it's those things that are all at work at the same time.

Kevin Smith with a room full of his own strain of pot, created for his new film, "Tusk." ; Credit: James Kim/KPCC

When Kevin Smith records his podcast, Smodcast, he says, "I'm usually blazed." Which, if you've heard the episode where Smith comes up with the entire story for his new film, "Tusk," it should come as no surprise.

The film is about a man who takes another man hostage and turns him into a walrus. While the movie itself doesn't mention or include any weed, Smith thought medical marijuana would be a nice complement to the viewing experience. 

A24, the film distribution company, came to Smith with a marketing idea: create strains of weed for the film. Smith thought it was genius. Buds and Roses — a cannabis dispensary in Studio City — was approached by Smith and his team to make medical marijuana specifically for the film. The dispensary came up with two strains called "Mr. Tusk" and "White Walrus." 

We met up with the director at Buds and Roses to see why the green substance was a perfect pairing for the film: 

Interview Highlights:

Smith knows that some people enjoy going to the movies stoned: 

"This movie, out of all movies, seems like a real head trip of a flick. So if they have their medical marijuana card, by all means, enjoy the movie. Don't feel the need to go back if you don't remember anything. It's not a gimmick to make them go twice or anything. But in a world where people are gonna smoke medicinal marijuana, having a 'Tusk' sticker on there just makes me smile. Kind of makes sense for this movie." 

How Fleetwood Mac and weed helped his writing:

"I put on Fleetwood Mac's 'Tusk' over and over on repeat and would just sit there and blaze while I wrote. And you know, I blaze in the way that I used to smoke cigarettes. So, I'll light it and put it in an ashtray, let it burn and stuff. So it fills the room like incense if you will. But, yeah, for a movie like 'Tusk,' I guess you gotta be pretty stoned to make the guy-who-makes-a-guy-into-a-walrus movie. And I'm kinda glad I did. It's weird. People are calling it the best movie I've ever made and I was like, 'Well, this is the only one I made stoned.' So I'm like, 'Guess what I'm doing, kids!'"

Smith used to be against drugs: 

"I smoked weed in my life, but I would never consider myself a stoner. In fact, I still had the '80s [attitude] lingering, 'Just say no,' and,  you know, 'Oh my lord! It's a drug!' It wasn't until I became older — age 38 — when I started smoking weed on a regular basis. I was like, 'This is not a drug. This is ridiculous! It grows in the Earth.' So once I got past the bias that was pounded into us in the '80s, suddenly I was like, 'Heavens. I like who I am here.' It doesn't make you a better person, kids. It doesn't make you more creative. What it does is it kind of knocks fear on its ass. You face your fears a little better." 

Disclaimer: Smith wants you to know that he does not endorse marijuana for anyone under 21:

"Kids, teenagers... I'm talking to you. The teenage brain is stunted by marijuana smoking so you guys have to wait 'til you're older. I didn't start smoking 'til I was 38 years old. I'm not saying wait 'til then. That was a stupid mistake on my behalf. But wait until you're legit. Wait until you're 21 before you start smoking." 

Source: Streetwise Reports 10/23/2024

Lithium Ionic Corp. (LTH:TSX.V; LTHCF:OTCQX; H3N:FSE) has announced the initiation of Engineering, Procurement, and Construction Management (EPCM) services for its flagship Bandeira Lithium Project in Minas Gerais, Brazil. Globally recognized engineering firm Hatch Ltd. will lead engineering and design services. Reta Engenharia, a leading Brazilian construction management firm, will manage construction. This significant milestone signals the project's progression into the construction and development phase as Lithium Ionic moves closer to production.

Key Highlights from the company press release:

• Hatch Ltd. has been awarded engineering and design services. Hatch is an internationally recognized engineering firm with extensive global experience in several commodities and a local presence in Brazil, including offices in Belo Horizonte, the capital city of Minas Gerais state. Hatch's involvement will bring world-class expertise and innovative solutions to the Bandeira Project, ensuring a streamlined and efficient development process.
• Reta Engenharia, a leading Brazilian construction management company, has been selected to provide construction management services for the Bandeira Project. With extensive experience in greenfield mining projects, Reta has supported both junior and large-cap producers, making them ideally suited to drive efficient and effective project outcomes. Their proven track record in managing greenfield projects, combined with their deep regional knowledge, will be instrumental in advancing the Bandeira Project towards production.
• Growing the Owner's Team: To support this transition to project development and ensure a smooth transition into production, Lithium Ionic is expanding the technical capabilities of its owner's team by bringing in experienced professionals to guide the Bandeira Project through the construction and operational readiness phases.

In the company's news release, Blake Hylands, CEO of Lithium Ionic, noted the importance of this transition, "Our momentum towards production is stronger than ever as we kick off the engineering and construction management phase with our esteemed partners, Hatch and Reta."

The Bandeira Project is advancing through the permitting process at both state and federal levels, with key approvals expected soon. Initial production is scheduled to begin in the second half of 2026, following the approval of the Licença Ambiental Concomitante (LAC) and subsequent Mining Concession and Operating License.

Lithium Sector Gains Momentum Amid Growing Demand

Visual Capitalist reported on September 29 that despite the price drop, lithium-ion battery demand is projected to increase ninefold by 2040. This move is driven by the continued growth of the EV market and broader electrification trends.

Greg Jones of BMO Capital Markets described new drill results from the Bandeira project as continuing to "highlight the exploration potential at the property" and suggested that these results could present opportunities for optimization.

This long-term growth trajectory supports the ongoing development of lithium projects like Lithium Ionic's Bandeira Project in Brazil, which aims to meet this increasing global demand.

As Forbes reported on October 8, lithium prices had fallen by nearly 90% since their peak in 2022.

This is attributed to an oversupply of the commodity and slower-than-expected electric vehicle (EV) sales. Despite these challenges, industry experts indicated that the sector was showing early signs of recovery.

Also, on October 8, Barry Dawes of Martin Place Securities highlighted that "the lithium market is showing strong signs of upturn" and suggested that lithium shortages are likely after 2027, reinforcing the long-term potential of the sector. His comments reflected a growing optimism for the post-2027 period. It is then that demand for lithium is expected to outstrip supply.

Lithium Ionic's Catalysts

Lithium Ionic's Bandeira Project is positioned as a critical development in Brazil's Lithium Valley. According to the company's investor presentation, this project is expected to deliver significant output. A Feasibility Study projects a 14-year mine life, producing 178,000 tonnes of spodumene concentrate annually. The post-tax net present value (NPV) is projected at US$1.3 billion with an internal rate of return (IRR) of 40%.

The company's strategic partnerships with Hatch and Reta, combined with the strong regional infrastructure in Minas Gerais, which includes renewable hydroelectric power and proximity to export markets, are expected to accelerate the development of the project. These factors are key drivers of Lithium Ionic's goal to become one of Brazil's major lithium producers, contributing to the growing global demand for lithium in the electric vehicle market.

Analysts on Lithium Ionic

Analysts have shown optimism about Lithium Ionic Corp., particularly regarding the potential of its Bandeira Lithium Project. Katie Lachapelle from Canaccord Genuity, in her September 10, 2024, research note, highlighted the company's progress in securing approvals for the Final Exploration Reports for the Bandeira and Outro Lado lithium properties.

Lachapelle emphasized that the next major catalyst would be the approval of the Licença Ambiental Concomitante (LAC), which is needed to begin construction at the Bandeira project. She maintained a Speculative Buy rating with a target price of CA$2.50, representing a potential upside of 303% from the price at the time of the report. Lachapelle also noted the company's CA$35 million cash balance following recent financing transactions but indicated that additional funds would be required to cover the estimated US$266 million in initial capital costs.

On October 8, 2024, Greg Jones of BMO Capital Markets provided further positive insights into Lithium Ionic's development. He described new drill results from the Bandeira project as continuing to "highlight the exploration potential at the property" and suggested that these results could present opportunities for optimization. Jones maintained an Outperform rating on the stock, with a target price of CA$1.25, reflecting a 40% potential return. He also emphasized that the company traded below the peer median, with its lithium carbonate equivalent valued at US$40 per ton, compared to US$60 for peers, marking it as undervalued. He further pointed out that Lithium Ionic was one of BMO's preferred lithium developers. [OWNERSHIP_CHART-11098]

Ownership and Share Structure

According to the company, management and insiders own 20% of the Lithium Ionic.

One of the insiders, President & Director Helio Diniz, owns 5.52%, Director Michael Lawrence Guy owns 5.10%, Director David Patrick Gower owns 2.56%, and Andre Rezende Gumaraes owns 2.52%, according to Reuters.

30% is held by institutional investors. Reuters reports Waratah Captial Advisors owns 7.01%, JGP Gestao de Recursos Ltda owns 2.69%, RBC Global Asset Management Inc owns 1.94%, Sprott Asset Management LP owns 1.55%, BMO Asset Management owns 1.30%, and IXIOS Asset Management SA owns 1.20%. The rest is retail.

Lithium Ionic has 158.58 million shares outstanding and 131.15 million free-float traded shares.

The company's market cap is CA$135 million, and it trades in a 52-week range of CA$0.41 - 2.24 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Lithium Ionic Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: LTH:TSX.V; LTHCF:OTCQX; H3N:FSE, )

Source: Peter Bell 11/04/2024

Liberty Gold Corp. (LGD:TSX; LGDTF:OTCQX) released the results of the first study, a prefeasibility study (PFS), of its flagship Black Pine project in Idaho, reported Canaccord Genuity analyst Peter Bell in an Oct. 10 research note.

"The completion of the prefeasibility study is a key step in advancing the project through permitting, bringing a Black Pine mine much closer to reality," Bell wrote. "This is positive."

885% Gain Possible

Canaccord Genuity has a CA$3.25 per share price target on the Canadian Idaho-based exploration and development company, trading at the time of the report at about CA$0.33 per share, noted Bell. These figures imply a potential return on investment of 885%.

Liberty is rated Speculative Buy.

Specifics of the PFS

Bell presented the details of the Black Pine operation as outlined in the PFS, based on reserves of 3,110,000 ounces (3.11 Moz) of 0.32 grams per ton (0.32 g/t) gold.

Average production is 183,000 ounces per year (183 Koz/year) gold for the first five years, peaking at about 231 Koz. The average annual production, based on a 50,000 ton per day throughput, over a 17-year life of mine (LOM) is 135 Koz.

The PFS has the head grade during years one through five at 0.45 g/t gold. Over the LOM, the head grade is 0.32 g/t gold and gold recoveries, 70.4%.

As for costs, operating costs are low at US$9.10 per ton processed. The all-in-sustaining cost (AISC) is US$1,205 per ounce (US$1,205/oz) of gold for years one through five and US$1,380/oz of gold for the LOM.

"We believe the study highlights a simple, lower-risk and long-lived operation with an attractive cost profile," Bell wrote. "We model Liberty achieving initial production at Black Pine in 2029, based on company disclosure around the permitting process."

Attractive Economics

Bell reported the economics outlined in the PFS for the base case using a US$2,000/oz gold price. The after-tax net present value discounted at 5% (NPV5%) is US$552 million, the internal rate of return (IRR) is 32%, and the payback period is 3.3 years. The strip ratio is low at 1.3.

"Of note is the study's leverage to higher gold prices with an NPV5% of US$1,296M (62% IRR at US$2,600/oz)," Bell wrote. At the same gold price, Canaccord Genuity's estimated NPV5% is higher, at US$1,569.

Bell noted that Liberty could enhance the value of Black Pine in any of four ways, by optimizing the resource and mine planning; delineating additional ounces or feed sources; using electric, maybe even autonomous, mining equipment; and defining options for using renewable energy like solar to potentially lower operating costs more.

How Results Stack Up

The analysts pointed out the similarities and differences between Liberty Gold's PFS and Canaccord Genuity's estimates on Black Pine. Between the two, the capex, AISC, mined throughput, and NPV are consistent, "which we view as positive," Bell wrote.

Among the parameters that differ are unit costs per ton processed, strip ratio, head grade, recovery, and total recovered ounces, all lower in the PFS. Mine life, though, is longer.

"The longer mine life and lower total ounce total equate to a lower number of ounces of annual production," Bell explained.

Process and general and administrative costs are lower in the PFS, which decreases the cutoff and the overall grade when compared to Canaccord Genuity's version. Bell indicated that the lower operating cost per ton, however, is positive.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Liberty Gold Corp. is a billboard sponsor of Streetwise Reports.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Canaccord Genuity, Liberty Gold Corp., October 10, 2024

Analyst Certification Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research, and (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer. Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account.

Sector Coverage Individuals identified as “Sector Coverage” cover a subject company’s industry in the identified jurisdiction, but are not authoring analysts of the report. Investment Recommendation Date and time of first dissemination: October 10, 2024, 09:56 ET Date and time of production: October 10, 2024, 09:56 ET Target Price / Valuation Methodology: Liberty Gold Corp. - LGD Our target price is based on a 0.85x multiple applied to our forward curve derived operating NAV less net debt and other corporate adjustments. Risks to achieving Target Price / Valuation: Liberty Gold Corp. - LGD In addition to the usual risks to target prices associated with commodity pricing, exchange rates, and mineral exploration/ development, we highlight the following: Commodity price risk: As a precious metals development company, LGD’s future revenue is dependent on the price of gold. Water rights: The Goldstrike Project does not currently have sufficient water rights to operate the proposed mine and heap leach. They announced June 1 that they have retained consultants to attempt to obtain water. Geo-political risk: Liberty is currently focussed on the western United States but retains exposure to Turkey through the TV-Tower project. Accordingly, Liberty’s operations could be adversely impacted by political or economic instability or changes in government policy that impact the ownership of assets, mining activities, exchange rates, taxation, or royalties in Turkey. We note that Liberty’s Turkish asset, TV-Tower, accounts for less than 3% of NAV in our valuation. Mining risk: LGD faces the typical risks inherent to mining companies relating to operating and capital costs, availability of capital, permitting requirements and timelines, technical and operating parameters, reserve and resource models, social license and community relations, taxation and royalty regimes, and regulatory and political risks. Black Pine does not currently have a published economic study so the estimates in our model are based on our own interpretation of how the operation may be designed. As such, our valuation of the Black Pine project may be impacted by differences in strip ratio, CapEx, mining throughput, recovery assumptions, and gold grade. Development risk: LGD is planning to develop the Black Pine and Goldstrike projects in Idaho and Utah respectively. The company faces risks associated with developing the project including capital and operating cost risk, financing, project permitting and timelines, and technical risks to achieve the planned operating rates. Permitting risk: Permitting is still underway at the Black Pine project. As such, the company may not be able to proceed with the project as it is currently envisaged if the required permits are not received in a timely manner. Financing risk: As a pre-cash-flow development company, LGD is reliant on the capital markets to remain a going concern. At present, the company has an estimated cash position of ~US$13.1M (Q2/24), which positions the company well in the near term to continue to advance its portfolio of exploration/development projects, in our view. We note that there is no guarantee that LGD will be able to access capital markets in the future as the result of potential changes in market sentiment/pricing and/or concerns involving project feasibility. As such, there is no guarantee that LGD will be able to secure the required funds to advance the Black Pine project, including but not limited to debt/equity financing and/or a strategic investment.

Required Company-Specific Disclosures (as of date of this publication) Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from Liberty Gold Corp. in the next three months.

Past performance In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance. Online Disclosures Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity’s policies and procedures regarding the dissemination of research by following the steps outlined above.

dissemination of research by following the steps outlined above. General Disclaimers See “Required Company-Specific Disclosures” above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, “Compendium Reports.” “Canaccord Genuity” is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80%-owned by Canaccord Genuity Group Inc. The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity LLC, a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne. The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity’s policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity’s policy is available upon request. The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity’s judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability. From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity’s affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research. This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

Research Distribution Policy Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity’s customers who are entitled to receive the firm's research. In addition research may be distributed by the firm’s sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity’s customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent. For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.

Short-Term Trade Ideas Research Analysts may, from time to time, discuss “short-term trade ideas” in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term ‘Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or “Speculative Buy’ could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity’s research.

For Canadian Residents: This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory. For United States Persons: Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. For United Kingdom and European Residents: This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority. For Jersey, Guernsey and Isle of Man Residents: This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser. CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc. For Australian Residents: This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052. This report should be read in conjunction with the Financial Services Guide available here - Financial Services Guide. For Hong Kong Residents: This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request. Copyright © Canaccord Genuity Corp. 2024 – Member CIRO/Canadian Investor Protection Fund Copyright © Canaccord Genuity Limited. 2024 – Member LSE, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2024 – Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited. 2024 – Participant of ASX Group, Cboe Australia and of the NSX. Authorized and regulated by ASIC. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above. None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.

( Companies Mentioned: LGD:TSX; LGDTF:OTCQX, )

Geologists from the Yellowstone Volcano Observatory are often asked to estimate how likely future eruptions are at Yellowstone, but it’s no walk in the national park.

Source: Dr. Robert Driscoll 10/28/2024

Wedbush analysts Dr. Robert Driscoll, Dr. Ritika Das, and Sam Ravina, in a research report published on October 28, 2024, maintained their Outperform rating on Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) while raising their price target to US$15.00 from US$11.00. The report follows Monte Rosa's announcement of a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program.

The analysts highlighted the significant financial terms of the agreement, stating, "GLUE will receive an upfront payment of US$150M as well as total milestone payments of up to US$2.1B that will include US$1.5B in potential development and regulatory milestones that begin upon Ph 2 studies."

Regarding the partnership structure, the analysts noted, "Upon start of Ph 3 studies, 30% US P&L would be shared with Ph 3 development co-fund and ex-US tiered royalties. Importantly, NVS will cover the complete costs of Ph 2 studies and will obtain worldwide rights to develop, commercialize and manufacture MRT-6160 as well as other VAV MGDs."

The analysts viewed this collaboration positively, stating, "We view this favorable collaboration agreement as an additional robust validation of GLUE's QuEEN MGD platform (noting Novartis' significant efforts in the degrader space), as well as an acknowledgment of the significant potential opportunities around targeting VAV1 with a first in class degrader."

They also emphasized the strategic benefits, noting, "Furthermore, we note the likely accelerated timelines for the MRT-6160 development program overall, and significant extension of GLUE's operational cash runway, which we expect to allow advancement of its deep pipeline."

The report highlighted the ongoing Phase 1 SAD/MAD healthy subject study for MRT-6160 in autoimmune diseases, with initial data expected in 1Q:25.

Wedbush's valuation methodology is based on sales multiples. The analysts explained, "Our PT is derived from applying a 6x multiple to estimated US sales and a 15x multiple to EU royalties of MRT-2359 in 2031, discounted by 30% annually."

The analysts also outlined several risk factors, including potential clinical and regulatory failure of MRT-2359, challenges in achieving sales estimates, and possible commercial competition from current and future therapies.

In conclusion, Wedbush's increased price target to US$15 reflects growing confidence in Monte Rosa Therapeutics following the Novartis collaboration agreement. The share price at the time of the report of US$8.05 represents a potential return of approximately 86% to the analysts' target price, highlighting the significant upside potential as the company advances its development programs with its new partner.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, Monte Rosa Therapeutics Inc., October 28, 2024

Analyst Certification We, Robert Driscoll, Ritika Das and Sam Ravina, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities. Company Specific Disclosures This information is subject to change at any time. 2. WS managed a public offering of securities for Monte Rosa Therapeutics within the last 12 months. 4. WS has received compensation for investment banking services from Monte Rosa Therapeutics within the last 12 months. 5. WS provided Monte Rosa Therapeutics with investment banking services within the last 12 months.

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: GLUE:NASDAQ, )

Lithium Ionic Corp. (LTH:TSX.V; LTHCF:OTCQX; H3N:FSE) has announced the initiation of Engineering, Procurement, and Construction Management (EPCM) services for its flagship Bandeira Lithium Project. See why the CEO Blake Hyland says that the company's momentum towards production is stronger than ever.

Washington State Department of Agriculture entomologist Chris Looney displays a dead Asian giant hornet, a sample sent from Japan and brought in for research last year in Blaine, Wash.; Credit: Elaine Thompson /AFP via Getty Images

Murder hornets. They're back.

Authorities in Washington state have announced that they've confirmed the first U.S. report this year of an Asian giant hornet, or Vespa mandarinia, in a town north of Seattle.

"Basically the only information we have is that a slightly dried out, dead specimen was collected off of a lawn in Marysville," said Sven Spichiger, managing entomologist with the state agriculture department, during a press conference.

"There really isn't even enough information to speculate on how it got there or how long it had been there," Spichiger added.

Because of its withered condition and the fact that male giant hornets don't typically emerge until July, agriculture officials believe the hornet discovered in early June was likely from a previous season and just recently found.

So-called "murder hornets" are native to Asia but have been spotted in Washington state and Canada over the past two years. The sting of the Vespa mandarinia can be life-threatening to humans, and the killer insects are known to wipe out the colonies of their fellow bugs, particularly honey bees.

According to genetic testing of the specimen discovered in Washington this month, the dead hornet was not the same as the other giant hornets discovered in North America since 2019. The hornet's coloration, which indicates it came from southern Asia, also suggested it arrived in "probably a separate event" than the ones previously known, Spichiger said.

But he emphasized that that was not necessarily cause for alarm.

"I want to very much clarify that a single dead specimen does not indicate a population," Spichiger said.

Washington agriculture officials are now setting murder hornet traps in the area of the discovery and are encouraging "citizen scientists" to do the same.

This content is from Southern California Public Radio. View the original story at SCPR.org.

In the country, autonomous mobility will probably mean robotic tractors rather than robotic cars, and if tractor maker Escorts has its way, they could get here sooner than thought.

The final stages of the 2011 property revaluation process in Catawba County have begun with the presentation of the proposed 2011 Schedule of Values to the Board of Commissioners, and will continue into November, when property owners will receive notice of the new value of their property, and into December and early 2011 when the appeal process begins.

Do you have any unwanted household products, such as paints, cleansers, solvents, antifreeze, batteries or used motor oils; or electronics like computer equipment, old radios, mobile phones, TVs, VCRs, calculators or copiers? Dispose of them properly, free of charge, on May 7th from 9 a.m. to 3 p.m.

The annual Foothills Regional Conference for Parent Educators will be held Friday, June 3 from 9:00am until 2:00pm at the Catawba County Cooperative Extension Center in Newton. The 2011 theme is Helping Families Do More with Less.

If the dilute and dispose approach for disposing of the surplus plutonium in the Waste Isolation Pilot Plant (WIPP) is fully implemented, the U.S. Department of Energy (DOE) should use two independent review teams to develop public trust in and improve its decisions, says a new interim report by the National Academies of Sciences, Engineering, and Medicine.

Most of the alternative technologies to open burning and open detonation (OB/OD) of conventional munitions designated for disposal are mature, including contained burn and contained detonation chambers with pollution control equipment, and many are permitted to replace OB/OD of waste munitions, says a new report by the National Academies of Sciences, Engineering, and Medicine.

The first-ever Nobel Prize Summit, Our Planet, Our Future, will bring together Nobel Laureates and other world-renowned experts and leaders to advance new insights into global sustainable development and explore actions that need to be taken to ensure humanity’s future on a prosperous, stable, and resilient planet.

Autonomous vehicles (AV) took center stage at the Chair’s Luncheon of the Transportation Research Board’s annual meeting today.

The U.S. Department of Energy’s plan to dilute and dispose of 34 metric tons of surplus plutonium in the Waste Isolation Pilot Plant (WIPP) in New Mexico is technically viable, provided that the plan’s implementation challenges and system vulnerabilities are resolved.

During Nobel Week 2021, ceremonial presentations of Nobel Prize medals and diplomas to 2021 laureates who are based in the United States will take place at the National Academy of Sciences.

This week, ESET experts released several research publications that shine the spotlight on a number of notable campaigns and broader developments on the threat landscape

As the UK mulls new rules for ransomware disclosure, what would be the wider implications of such a move, how would cyber-insurance come into play, and how might cybercriminals respond?

A facial recognition system misidentifies a woman in London as a shoplifter, igniting fresh concerns over the technology's accuracy and reliability

Ticketmaster seems to have experienced a data breach, with the ShinyHunters hacker group claiming to have exfiltrated 560 million customer data

The spyware, called AridSpy by ESET, is distributed through websites that pose as various messaging apps, a job search app, and a Palestinian Civil Registry app

Understanding and preparing for the potential long-tail costs of data breaches is crucial for businesses that aim to mitigate the impact of security incidents

Learn about the types of threats that 'topped the charts' and the kinds of techniques that bad actors leveraged most commonly in the first half of this year

Social media sites are designed to make their users come back for more. Do laws restricting children's exposure to addictive social media feeds have teeth or are they a political gimmick?

Blanket bans on ransomware payments are a much-debated topic in cybersecurity and policy circles. What are the implications of outlawing the payments, and would the ban be effective?

A purported ad blocker marketed as a security solution leverages a Microsoft-signed driver that inadvertently exposes victims to dangerous threats

Attackers abusing the EvilVideo vulnerability could share malicious Android payloads via Telegram channels, groups, and chats, all while making them appear as legitimate multimedia files

Organizations that leveraged AI and automation in security prevention cut the cost of a data breach by $2.22 million compared to those that didn't deploy these technologies

Unsurprisingly, many discussions revolved around the implications of the CrowdStrike outage, including the lessons it may have offered for bad actors

Business email compromise (BEC) has once again proven to be a costly issue, with a company losing $60 million in a wire transfer fraud scheme

Phishing using PWAs? ESET Research's latest discovery might just ruin some users' assumptions about their preferred platform's security

The discovery of the NGate malware by ESET Research is another example of how sophisticated Android threats have become

The schemes disproportionately victimize senior citizens, as those aged 60 or over were more than three times as likely as younger adults to fall prey to the scams

ESET researchers also find that CosmicBeetle attempts to exploit the notoriety of the LockBit ransomware gang to advance its own ends

With just weeks to go before the US presidential election, the FBI and the CISA are warning about attempts to sow distrust in the electoral process

ESET research examines the group's malicious wares as used to spy on targets in Ukraine in the past two years

Attributing a cyberattack to a specific threat actor is a complex affair, as evidenced by new ESET research published this week

ESET research dives deep into a series of attacks that leveraged bespoke toolsets to compromise air-gapped systems belonging to governmental and diplomatic entities

The average time it takes attackers to weaponize a vulnerability, either before or after a patch is released, shrank from 63 days in 2018-2019 to just five days last year

As methane emissions come under heightened global scrutiny, learn how a state-of-the-art satellite can pinpoint their sources and deliver the insights needed for targeted mitigation efforts

Election interference, American Water and the Internet Archive breaches, new cybersecurity laws, and more – October saw no shortage of impactful cybersecurity news stories

Today, I am inviting Temo, who is from the academic discipline marketing team, and he looks after the physics discipline. He will share his Pick from the field of optics.This week's Pick is MCmatlab... read more >>

NASA's Terra satellite and a NASA animation of imagery from NOAA's GOES-West satellite provided views of Hurricane Newton as it neared landfall in Baja California, Mexico, today, Sept. 6.

read more

NASA's Aqua satellite passed over the U.S. Southwest and captured infrared data on the clouds associated with former Tropical Cyclone Newton.

read more

He has been in the spotlight in recent weeks after the launch of the first investigations under a new EU law into X (formerly Twitter), Facebook owner Meta and TikTok over the spread of false information and hate speech following the Hamas-Israel conflict.

Singapore-based data centre operator Princeton Digital Group (PDG) on Thursday announced to invest $1 billion in India and expand capacity to a total of 230 MW in the country.

The sandwich features sweet and crispy maple flavored waffles with sizzling bacon or sausage, melted American cheese, and a freshly cracked egg.